IMA ImageneBio, Inc.
Financings ·
The warrants cover up to 5,770,335 shares at $5.199 per warrant share, with closing expected on or about April 14, 2026. ImageneBio plans to use the proceeds for its IMG-007 programs.
Ikena Oncology, now ImageneBio, closed its merger with Inmagene Biopharmaceuticals on July 25, 2025. It issued contingent value rights to both sets of shareholders, which pay only from proceeds of selected assets, and it took on a transition services deal with a company owned by Inmagene's legacy holders.
A July 2025 corporate overview says the merger closed and that the company has raised $140 million to date. Its lead drug, IMG-007, is in a Phase 2b trial in atopic dermatitis.
Inmagene dosed the first patient in its ADAPTIVE trial of IMG-007 in atopic dermatitis, with topline results expected in the fourth quarter of 2026. Ikena filed the news as merger material.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $800,000 | $3.5 million |
| Research and development | $28.5 million | $32.1 million |
| Net income (loss) | -$45.3 million | -$36.6 million |
| Cash from operations | -$47.8 million | -$21.3 million |
| Cash and equivalents | $94.5 million | $12.1 million |
| Short-term investments | $40.8 million | $0 |
Our latest story on this, dated Apr 13, 2026: "ImageneBio agrees to sell pre-funded warrants for about $30 million in private placement". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jul 29, 2025: "Ikena Oncology (now ImageneBio) completes Inmagene merger, issues contingent value rights". The story links the filing or release it is based on. Read the story.
ImageneBio, Inc. trades under the ticker IMA on NASDAQ.
ImageneBio, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for ImageneBio, Inc. is 1835579. Its filings are on SEC EDGAR.
11,351,456 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-05.
Our directory records ImageneBio, Inc. under United States.
Our directory classifies ImageneBio, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for ImageneBio, Inc. is US45175G2075.
aibio.space lists ImageneBio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
$800,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
ImageneBio, Inc. reported a net loss of $45.3 million for the fiscal year ended Dec 31, 2025, and used $47.8 million of cash in operations, per its annual report to the SEC.
$28.5 million in the fiscal year ended Dec 31, 2025, per its annual report.
$136.2 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02). Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,8.01,9.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,3.02,3.03,5.01,5.02,5.03,5.06,7.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 8.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,8.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 7.01,8.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.02,5.01,5.02,7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio